Patients who have been labeled with a penicillin allergy may now have a chance at being delabeled without the need for specialist intervention or extensive testing, according to a recent study. Ibrahim Shah, MD, from the Indiana University School of Medicine, presented findings from a quality-improvement project conducted at a community hospital where 56 inpatients had a documented penicillin allergy in their electronic health records (EHR). Out of these patients, 38 were successfully delabeled either through medical history assessment or by undergoing an oral challenge without skin testing.
Dr. Shah reported that the study achieved a 95% success rate using oral challenges and a delabeling rate of 67%. This approach proved to be effective, carried minimal risk, and required fewer resources compared to traditional methods that involve allergists or infectious disease specialists. However, the long-term sustainability of these results is questionable, as 13% of patients had the penicillin allergy label re-added to their EHRs after 7 months. This aligns with current literature, which suggests that 12%-50% of patients retain a penicillin allergy label even after successful delabeling.
Dr. Shah highlighted the misconceptions surrounding penicillin allergies, stating that a significant number of patients falsely carry this label. He explained that many individuals develop rashes associated with penicillin or other medications during childhood, but these reactions are often mild and unrelated to penicillin. Furthermore, these allergies tend to be outgrown by adulthood, yet the label remains in medical records. This overlabeling adversely affects patient care by limiting their antibiotic treatment options, which can have serious consequences.
By directly delabeling patients based on medical history and risk evaluation, Shah’s study demonstrated that the need for skin testing followed by an oral challenge can be bypassed, reducing the burden on healthcare systems. Out of the 56 patients in the study, 18 were delabeled using only their medical history and were never administered penicillin. Another 27 patients were categorized as low or very low risk for penicillin allergy, allowing them to proceed to oral challenges. Only 10 patients were considered medium risk, and one patient was classified as high risk according to the PENFAST decision tool.
The research conducted by Dr. Shah and his colleagues during a two-month period in 2022 sheds light on the importance of reevaluating penicillin allergy labels and the potential consequences they pose for patient care. Dr. Werner Bischoff from Wake Forest University School of Medicine emphasized the need for programs that confirm penicillin allergies to reduce the limitations patients face in receiving appropriate antibiotic treatment. While pharmacists are emerging as valuable contributors to delabeling programs, their limited provider status in some states poses a barrier to widespread implementation. Efforts should be made to expand the role of pharmacists in these programs and standardize allergy evaluation protocols.
The study conducted by Dr. Shah presents a promising approach to delabeling patients with a penicillin allergy, offering a safer alternative that requires fewer resources and does not rely on specialist intervention. By challenging the accuracy of penicillin allergy labels and actively delabeling patients based on risk evaluation, healthcare providers can improve patient outcomes and provide more appropriate antibiotic treatment options. Moving forward, it is crucial to raise awareness about the prevalence of overlabeling and advocate for the implementation of delabeling programs that involve pharmacists as key members of the healthcare team.
Leave a Reply